Compare OXSQ & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXSQ | SGMO |
|---|---|---|
| Founded | 2003 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.1M | 155.1M |
| IPO Year | N/A | 2000 |
| Metric | OXSQ | SGMO |
|---|---|---|
| Price | $1.78 | $0.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $4.71 |
| AVG Volume (30 Days) | 788.1K | ★ 9.1M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 23.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,142,565.00 | $32,875,000.00 |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | $2.27 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.56 | $0.38 |
| 52 Week High | $2.87 | $2.84 |
| Indicator | OXSQ | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 39.22 | 40.49 |
| Support Level | $1.82 | $0.49 |
| Resistance Level | $1.87 | $0.46 |
| Average True Range (ATR) | 0.04 | 0.03 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 16.83 | 10.03 |
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.